Another piece of M&A rumour in the news. Employees are becoming accustomed to hearing their company either merging with another or buying (or being bought out) by another company.
Actelion standing their ground is good news for their employees. Continuing to operate as Actelion and fending off any interested parties will no doubt create stability and loyalty to their staff.
Have you been caught up in the whirlwind of M&A? How does it make you feel?
Clozel’s remarks come in the wake of a media report that cited the Swiss biotech as a potential buy for big guns Sanofi and Johnson & Johnson. But it’s hardly the first time the company has been thrown around as a deal target; it’s come up for years on industry watchers’ likely-to-be-bought lists, and its tax-advantaged locale sparked extra interest during the inversion craze. Actelion, though, has made it clear time and again that it wants to fly solo--and lately, Clozel thinks that’ll be even easier to do. The drugmaker is becoming “more and more expensive” as its shares pick up steam, which they’ve done over the past year thanks to consensus-beating sales of the company’s heart meds.